# GLP-1 receptor agonists: Materials

Source page: https://www.materialinsights.org/technologies/glp1_agonists/tech-materials/

#### Materials it needs

The commodities and chemicals it needs per unit, its share of each one's demand and how critical each is
 Made of

- [Pep Peptides and oligonucleotides](https://www.materialinsights.org/chemicals/peptides_oligos/) criticality medium The active ingredient is a peptide, a short chain of amino acids, modified to resist breakdown ^[1].
 Uses

- [Lys Amino acids (lysine, methionine)](https://www.materialinsights.org/chemicals/amino_acids/) criticality low Peptides are built from amino acids, either by chemical synthesis or in engineered cells.
- [Exc Pharmaceutical excipients](https://www.materialinsights.org/chemicals/excipients/) criticality low Salts, buffers and preservatives keep the peptide stable in the injection pen.
 Needs

- [Qz Silica sand](https://www.materialinsights.org/commodities/industrial_sand/) criticality low The medicine is held in glass cartridges or vials, and glass is made mainly from silica sand.

as of 2026-11-11. No source gives material amounts per dose; criticality is the writer's judgement. Peptides rank medium because supply is tight: WHO says that even with rapid expansion in production, the medicines are projected to reach fewer than 10% of those who could benefit by 2030 [3].

#### Critical materials

The materials whose supply could hold it back

- No scarce raw material holds these medicines back: amino acids and excipients are made in large amounts for other uses.
- Supply falls far short of need: even with rapid expansion in production, WHO projects the medicines will reach fewer than 10% of those who could benefit by 2030, and it calls for action on manufacturing and affordability ^[3].
- Supply is concentrated in a few companies; Novo Nordisk says it holds 45.8% of the GLP-1 diabetes market by value ^[5].

as of 2026-11-11

#### Sources

1. [GLP-1-based therapy for obesity](https://laskerfoundation.org/winners/glp-1-based-therapy-for-obesity/) Lasker Foundation (2024 Lasker~DeBakey Clinical Medical Research Award), 2024
2. [WHO issues global guideline on the use of GLP-1 medicines in treating obesity](https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity) World Health Organization, 2025
3. [Financial report for the period 1 January 2025 to 31 December 2025 (company announcement No 4/2026, Form 6-K)](https://www.sec.gov/Archives/edgar/data/353278/000035327826000006/caq42025.htm) Novo Nordisk A/S, filed with the US Securities and Exchange Commission, 2026

## Other sections

- [Summary](https://www.materialinsights.org/technologies/glp1_agonists/index.md)
- [Overview](https://www.materialinsights.org/technologies/glp1_agonists/tech-overview/index.md)
- [Science](https://www.materialinsights.org/technologies/glp1_agonists/tech-science/index.md)
- [Evolution](https://www.materialinsights.org/technologies/glp1_agonists/tech-evolution/index.md)
- [Energy footprint](https://www.materialinsights.org/technologies/glp1_agonists/tech-energy-footprint/index.md)
- [Industries](https://www.materialinsights.org/technologies/glp1_agonists/tech-industries/index.md)
